Physostigmine (Compound)

Synonyms:physostigmine, Eserine, 57-47-6, Antilirium, Physostol, Esromiotin, Ezerin, Calabarine, Erserine, Fysostigmin, (-)-physostigmine, (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate, Eserolein, methylcarbamate (ester), UNII-9U1VM840SP, Eserine sulfate, CHEMBL94, 9U1VM840SP, CHEBI:27953, NSC30782, NSC-30782, NCGC00093889-03, DSSTox_CID_3471, DSSTox_RID_77040, DSSTox_GSID_23471, Fysostigmin [Czech], [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate, CHEMBL537674, Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, CAS-57-47-6, CCRIS 3422, HSDB 3161, MCV 4484, EINECS 200-332-8, Eserolein, methylcarbamate, NIH 10421, NSC 30782, Physostigmine [USP:BAN], RCRA waste no. P204, physostigmin, CS 58525, Methyl-carbamic acid, ester with eseroline, Carbamic acid, methyl-, ester with eseroline, (-) physostigmine, Eserine (TN), Physostigmine (USP), Physostigmine free base, Spectrum_000916, Spectrum_001789, SpecPlus_000381, Prestwick0_000566, Prestwick1_000566, Prestwick2_000566, Prestwick3_000566, Spectrum2_000330, Spectrum2_000757, Spectrum2_001283, Spectrum3_000545, Spectrum3_000901, Spectrum4_000997, Spectrum4_001631, Spectrum4_001913, Spectrum5_000441, Spectrum5_000626, Spectrum5_001672, physostigmine.salicylic acid, 1,2,3,3abeta,8abeta-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)-indol-5-yl methylcarbamate, Lopac0_000483, SCHEMBL24044, BSPBio_000352, BSPBio_002189, KBioGR_001433, KBioGR_002061, KBioGR_002533, KBioSS_001396, KBioSS_002279, (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol methylcarbamate (ester), MLS001304022, DivK1c_006477, SPECTRUM1500753, SPBio_000339, SPBio_000774, SPBio_001285, SPBio_002571, BPBio1_000388, cid_657348, GTPL6598, MEGxp0_001872, DTXSID3023471, ACon1_000097, BDBM11023, KBio1_001421, KBio2_001396, KBio2_002278, KBio2_003964, KBio2_004846, KBio2_006532, KBio2_007414, KBio3_001689, KBio3_001842, Eserine, >=98.0% (N)

Pubchem:PUBCHEM:5983

Id:5983

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Physostigmine's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Physostigmine.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Physostigmine.

Results found

Linked to

	Label	Description
	BRD-K25650355-059-12-2 Substance (Entity type)	A Substance
	physostigmine (c2f11a47-a6de-4ee6-bcf7-041059893256) Collection (Entity type)	Metadatata for physostigmine
	DCSTRUCT ID 02159 Collection (Entity type)	DrugPage Collection: (DrugCentralID:02159; PubChem_CID:5983, FILE=drugcentral_drug_02159.json)
	Physostigmine negatively regulates NRN1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Physostigmine positively regulates KRT18 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Physostigmine in similarity relationship with hydrazinecarboximidamide Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Physostigmine negatively regulates CYP1B1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Physostigmine positively regulates TMT1A Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Physostigmine negatively regulates BTG1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Physostigmine negatively regulates KLF10 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS